<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01667068</url>
  </required_header>
  <id_info>
    <org_study_id>12-4970-BO</org_study_id>
    <nct_id>NCT01667068</nct_id>
  </id_info>
  <brief_title>Cardiovascular Diseases in HIV-infected Patients HIV-HEART Study: 7.5 Years Follow-up</brief_title>
  <official_title>HIV-HEART STUDY: A Prospective, Epidemiologic and Multicentre Trial to Determine the Cardiovascular Risk in HIV-infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HIV-HEART Study Investigative Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Heart Failure Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen-Cilag GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Essen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since the introduction of antiretroviral therapy life expectancy of HIV-infected persons is&#xD;
      rising. Different cohorts are observing an increased risk for cardiovascular diseases in this&#xD;
      aging HIV-infected population. Traditional cardiovascular risk factors like smoking are more&#xD;
      frequent in HIV-infected persons. For example chronic inflammation due to HIV-infection and&#xD;
      metabolic disorders also caused by some antiretroviral substances as special non-traditional&#xD;
      risk factors in HIV-infected persons can influence the development of cardiovascular diseases&#xD;
      additionally. Therefore new research focus in special risk profile associated with&#xD;
      HIV-infection or antiretroviral treatment and prevention for HIV-infected patients is&#xD;
      developing.&#xD;
&#xD;
      This present study is an ongoing prospective regional multicenter trial that was conducted to&#xD;
      analyse the incidence, prevalence and clinical course of cardiovacular disorders in&#xD;
      HIV-infected out-patients.&#xD;
&#xD;
      Cardiac disorders witch are associated with HIV are pericarditis, pleural effusion, pulmonary&#xD;
      hypertension, dilated cardiomyopathy, heart failure, myocarditis, bacterial endocarditis and&#xD;
      heart valve disorders. In addition to previously stated disorders of the heart, the premature&#xD;
      atherosclerosis of coronary arteries, a further even more important disease of the heart in&#xD;
      this patient population, went into the focus of most HIV-researchers and physicians.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A comprehensive detailed description of the study procedures had been previously published&#xD;
      (European Journal of medical research 2007;12:243-248).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular Diseases in HIV-infected Patients</measure>
    <time_frame>Baseline up to 7.5 follow-up to</time_frame>
    <description>The detection of prevalence, aetiology, progression and severity of cardiovascular diseases - especially of coronary artery disease in HIV-infected patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Disorders in HIV-infected Patients HIV-HEART</measure>
    <time_frame>Baseline up to 5 years follow-up</time_frame>
    <description>Complementary the study also investigates the impact of classic cardiovascular risk factors like gender, age, blood fat and also new HIV-specific risk factors of coronary artery disease like viral-load, CD4-cell count and stage of the infection. The HIV-HEART study will focus the impact of medication including cardiovascular and antiretroviral medication. Further secondary objectives will be examined, including economic costs and the subjectively quality of life of subjects with and without cardiovascular diseases in this patient population.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1481</enrollment>
  <condition>Coronary Heart Disease</condition>
  <condition>Heart Failure</condition>
  <condition>HIV</condition>
  <condition>AIDS</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Regional Ruhrgebiets Cohort</arm_group_label>
    <description>HIV-positive patients in the German Ruhr-Region from out-patient clinics of hospitals and HIV-physicians pratices</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Comprehensive non invasive cardiovascular examination</intervention_name>
    <description>Anamnesis with the participian&#xD;
File recherche,Physical examination&#xD;
Documentation of the carciovascular and antiretroviral medical therapy&#xD;
Electrocardiogram&#xD;
Transthoracic echocardiography&#xD;
Exercise electrocardiogram&#xD;
Measuring of the arterial media thickness&#xD;
Exercise Montreal Cognitive Assesment test&#xD;
Exercise the Grooved Pegboard test&#xD;
Blood collection&#xD;
Questionnaire to quality of life and health economics</description>
    <arm_group_label>Regional Ruhrgebiets Cohort</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stored blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participiants were included in several cities of the Ruhrarea. Locations were Essen,&#xD;
        Bochum, Dortmund and Duisburg The study population included outpatients who were at least&#xD;
        18 years of age, had a known HIV-infection and exhibited a stable disease status within 4&#xD;
        weeks before inclusion of the trial. Written informed consent was obtained from all&#xD;
        participants.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Known HIV-infection&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute cardiovascular disease&#xD;
&#xD;
          -  Unstable hemodynamic status in the three weeks before inclusion&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Esser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Essen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Till Neumann Neumann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Essen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Bochum, Department of Dermatology</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIV Outpatient Department</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Center</name>
      <address>
        <city>Duisburg</city>
        <zip>47249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Department of Dermatology and Venerology</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, West German Heart Center Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Coordinating Center Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04107</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Neumann T. [HIV, AIDS and the cardiovascular risk]. Internist (Berl). 2008 Apr;49(4):429-30, 432-5. doi: 10.1007/s00108-008-2049-4. German.</citation>
    <PMID>18305915</PMID>
  </results_reference>
  <results_reference>
    <citation>Reinsch N, Buhr C, Krings P, Kaelsch H, Kahlert P, Konorza T, Neumann T, Erbel R; Competence Network of Heart Failure. Effect of gender and highly active antiretroviral therapy on HIV-related pulmonary arterial hypertension: results of the HIV-HEART Study. HIV Med. 2008 Aug;9(7):550-6. doi: 10.1111/j.1468-1293.2008.00602.x. Epub 2008 Jun 28.</citation>
    <PMID>18557952</PMID>
  </results_reference>
  <results_reference>
    <citation>Reinsch N, Buhr C, Krings P, Kaelsch H, Neuhaus K, Wieneke H, Erbel R, Neumann T; German Heart Failure Network. Prevalence and risk factors of prolonged QTc interval in HIV-infected patients: results of the HIV-HEART study. HIV Clin Trials. 2009 Jul-Aug;10(4):261-8. doi: 10.1310/hct1004-261.</citation>
    <PMID>19723613</PMID>
  </results_reference>
  <results_reference>
    <citation>Neumann T, Reinsch N, Neuhaus K, Brockmeyer N, Potthoff A, Esser S, Hower M, Neumann A, Mostardt S, Gelbrich G, Erbel R; fur die HIV-HEART-Studie sowie die Kompetenznetze Herzinsuffizienz und HIV/AIDS. [BNP in HIV-infected patients]. Herz. 2009 Dec;34(8):634-40. doi: 10.1007/s00059-009-3313-7. German.</citation>
    <PMID>20024643</PMID>
  </results_reference>
  <results_reference>
    <citation>Neumann T, Esser S, Potthoff A, Pankuweit S, Neumann A, Breuckmann F, Neuhaus K, Kondratieva J, Buck T, Muller-Tasch T, Wachter R, Prettin C, Gelbrich G, Herzog W, Pieske B, Rauchhaus M, Loffler M, Maisch B, Mugge A, Wasem J, Gerken G, Brockmeyer NH, Erbel R; HIV-HEART Study Investigative Group. Prevalence and natural history of heart failure in outpatient HIV-infected subjects: rationale and design of the HIV-HEART study. Eur J Med Res. 2007 Jun 27;12(6):243-8.</citation>
    <PMID>17666313</PMID>
  </results_reference>
  <results_reference>
    <citation>Breuckmann F, Neumann T, Kondratieva J, Wieneke H, Ross B, Nassenstein K, Barkhausen J, Kreuter A, Brockmeyer N, Erbel R. Dilated cardiomyopathy in two adult human immunodeficiency positive (HIV+) patients possibly related to highly active antiretroviral therapy (HAART). Eur J Med Res. 2005 Sep 12;10(9):395-9.</citation>
    <PMID>16183552</PMID>
  </results_reference>
  <results_reference>
    <citation>Reinsch N, Kahlert P, Esser S, Sundermeyer A, Neuhaus K, Brockmeyer N, Potthoff A, Erbel R, Buck T, Neumann T. Echocardiographic findings and abnormalities in HIV-infected patients: results from a large, prospective, multicenter HIV-heart study. Am J Cardiovasc Dis. 2011;1(2):176-84. Epub 2011 Jul 30.</citation>
    <PMID>22254197</PMID>
  </results_reference>
  <results_reference>
    <citation>Lind A, Reinsch N, Neuhaus K, Esser S, Brockmeyer NH, Potthoff A, Pankuweit S, Erbel R, Maisch B, Neumann T. Pericardial effusion of HIV-infected patients ? Results of a prospective multicenter cohort study in the era of antiretroviral therapy. Eur J Med Res. 2011 Nov 10;16(11):480-3. doi: 10.1186/2047-783x-16-11-480.</citation>
    <PMID>22027640</PMID>
  </results_reference>
  <results_reference>
    <citation>Gelbrich B, Neumann T, Esser S, Potthoff A, Reinsch N, Hower M, Dannhauer KH, Loeffler M, Brockmeyer NH, Erbel R, Gelbrich G; HIV-HEART Study Investigative Group, Competence Networks Heart Failure and HIV/AIDS. Oral health and the heart - does HIV infection open a pathophysiological gateway? Int J Cardiol. 2011 Sep 1;151(2):254-7. doi: 10.1016/j.ijcard.2011.06.081. Epub 2011 Jul 18. No abstract available.</citation>
    <PMID>21764468</PMID>
  </results_reference>
  <results_reference>
    <citation>Reinsch N, Neuhaus K, Esser S, Potthoff A, Hower M, Mostardt S, Neumann A, Brockmeyer NH, Gelbrich G, Erbel R, Neumann T; German Competence Network Heart Failure; German Competence Network for HIV/AIDS. Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study. Eur J Prev Cardiol. 2012 Apr;19(2):267-74. doi: 10.1177/1741826711398431. Epub 2011 Feb 28.</citation>
    <PMID>21450595</PMID>
  </results_reference>
  <results_reference>
    <citation>Reinsch N, Neuhaus K, Esser S, Potthoff A, Hower M, Brockmeyer NH, Erbel R, Neumann T; German Competence Network for Heart Failure; German Competence Network for HIV AIDS. Prevalence of cardiac diastolic dysfunction in HIV-infected patients: results of the HIV-HEART study. HIV Clin Trials. 2010 May-Jun;11(3):156-62. doi: 10.1310/hct1103-156.</citation>
    <PMID>20739268</PMID>
  </results_reference>
  <results_reference>
    <citation>Potthoff A, Brockmeyer NH, Gelbrich G, Neuhaus K, Esser S, Reinsch N, Hower M, Mostardt S, Neumann A, Neumann T; Competence Center Cardiac Insufficiency and the Competence Network HIV/AIDS. Lipodystrophy - a sign for metabolic syndrome in patients of the HIV-HEART study. J Dtsch Dermatol Ges. 2010 Feb;8(2):92-8. doi: 10.1111/j.1610-0387.2009.07330.x. Epub 2009 Dec 14. English, German.</citation>
    <PMID>20002869</PMID>
  </results_reference>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>August 16, 2012</study_first_submitted>
  <study_first_submitted_qc>August 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2012</study_first_posted>
  <last_update_submitted>October 27, 2014</last_update_submitted>
  <last_update_submitted_qc>October 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Essen</investigator_affiliation>
    <investigator_full_name>Stefan Esser M.D.</investigator_full_name>
    <investigator_title>Academic Director</investigator_title>
  </responsible_party>
  <keyword>Cardiac Diseases</keyword>
  <keyword>HIV-Infection</keyword>
  <keyword>AIDS</keyword>
  <keyword>Antiretroviral Therapy</keyword>
  <keyword>Cardiovascular Medication</keyword>
  <keyword>Risk Factors</keyword>
  <keyword>coronary heart disease</keyword>
  <keyword>heart failure</keyword>
  <keyword>metabolic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT01667068
org study id: 12-4970-BO
nct id: NCT01667068
lead sponsor: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
has dmc: Yes
Since the introduction of antiretroviral therapy life expectancy of HIV-infected persons is
      rising. Different cohorts are observing an increased risk for cardiovascular diseases in this
      aging HIV-infected population. Traditional cardiovascular risk factors like smoking are more
      frequent in HIV-infected persons. For example chronic inflammation due to HIV-infection and
      metabolic disorders also caused by some antiretroviral substances as special non-traditional
      risk factors in HIV-infected persons can influence the development of cardiovascular diseases
      additionally. Therefore new research focus in special risk profile associated with
      HIV-infection or antiretroviral treatment and prevention for HIV-infected patients is
      developing.

      This present study is an ongoing prospective regional multicenter trial that was conducted to
      analyse the incidence, prevalence and clinical course of cardiovacular disorders in
      HIV-infected out-patients.

      Cardiac disorders witch are associated with HIV are pericarditis, pleural effusion, pulmonary
      hypertension, dilated cardiomyopathy, heart failure, myocarditis, bacterial endocarditis and
      heart valve disorders. In addition to previously stated disorders of the heart, the premature
      atherosclerosis of coronary arteries, a further even more important disease of the heart in
      this patient population, went into the focus of most HIV-researchers and physicians.
A comprehensive detailed description of the study procedures had been previously published
      (European Journal of medical research 2007;12:243-248).
observational model: Cohort
time perspective: Prospective
measure: Cardiovascular Diseases in HIV-infected Patients
time frame: Baseline up to 7.5 follow-up to
description: The detection of prevalence, aetiology, progression and severity of cardiovascular diseases - especially of coronary artery disease in HIV-infected patients.
measure: Cardiovascular Disorders in HIV-infected Patients HIV-HEART
time frame: Baseline up to 5 years follow-up
description: Complementary the study also investigates the impact of classic cardiovascular risk factors like gender, age, blood fat and also new HIV-specific risk factors of coronary artery disease like viral-load, CD4-cell count and stage of the infection. The HIV-HEART study will focus the impact of medication including cardiovascular and antiretroviral medication. Further secondary objectives will be examined, including economic costs and the subjectively quality of life of subjects with and without cardiovascular diseases in this patient population.
arm group label: Regional Ruhrgebiets Cohort
description: HIV-positive patients in the German Ruhr-Region from out-patient clinics of hospitals and HIV-physicians pratices
intervention type: Other
intervention name: Comprehensive non invasive cardiovascular examination
description: Anamnesis with the participian
File recherche,Physical examination
Documentation of the carciovascular and antiretroviral medical therapy
Electrocardiogram
Transthoracic echocardiography
Exercise electrocardiogram
Measuring of the arterial media thickness
Exercise Montreal Cognitive Assesment test
Exercise the Grooved Pegboard test
Blood collection
Questionnaire to quality of life and health economics
arm group label: Regional Ruhrgebiets Cohort
Stored blood samples
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Stefan Esser, MD
role: Principal Investigator
affiliation: University Hospital, Essen
last name: Till Neumann Neumann, MD
role: Principal Investigator
affiliation: University Hospital, Essen
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: Germany
citation: Neumann T. [HIV, AIDS and the cardiovascular risk]. Internist (Berl). 2008 Apr;49(4):429-30, 432-5. doi: 10.1007/s00108-008-2049-4. German.
PMID: 18305915
citation: Reinsch N, Buhr C, Krings P, Kaelsch H, Kahlert P, Konorza T, Neumann T, Erbel R; Competence Network of Heart Failure. Effect of gender and highly active antiretroviral therapy on HIV-related pulmonary arterial hypertension: results of the HIV-HEART Study. HIV Med. 2008 Aug;9(7):550-6. doi: 10.1111/j.1468-1293.2008.00602.x. Epub 2008 Jun 28.
PMID: 18557952
citation: Reinsch N, Buhr C, Krings P, Kaelsch H, Neuhaus K, Wieneke H, Erbel R, Neumann T; German Heart Failure Network. Prevalence and risk factors of prolonged QTc interval in HIV-infected patients: results of the HIV-HEART study. HIV Clin Trials. 2009 Jul-Aug;10(4):261-8. doi: 10.1310/hct1004-261.
PMID: 19723613
citation: Neumann T, Reinsch N, Neuhaus K, Brockmeyer N, Potthoff A, Esser S, Hower M, Neumann A, Mostardt S, Gelbrich G, Erbel R; fur die HIV-HEART-Studie sowie die Kompetenznetze Herzinsuffizienz und HIV/AIDS. [BNP in HIV-infected patients]. Herz. 2009 Dec;34(8):634-40. doi: 10.1007/s00059-009-3313-7. German.
PMID: 20024643
citation: Neumann T, Esser S, Potthoff A, Pankuweit S, Neumann A, Breuckmann F, Neuhaus K, Kondratieva J, Buck T, Muller-Tasch T, Wachter R, Prettin C, Gelbrich G, Herzog W, Pieske B, Rauchhaus M, Loffler M, Maisch B, Mugge A, Wasem J, Gerken G, Brockmeyer NH, Erbel R; HIV-HEART Study Investigative Group. Prevalence and natural history of heart failure in outpatient HIV-infected subjects: rationale and design of the HIV-HEART study. Eur J Med Res. 2007 Jun 27;12(6):243-8.
PMID: 17666313
citation: Breuckmann F, Neumann T, Kondratieva J, Wieneke H, Ross B, Nassenstein K, Barkhausen J, Kreuter A, Brockmeyer N, Erbel R. Dilated cardiomyopathy in two adult human immunodeficiency positive (HIV+) patients possibly related to highly active antiretroviral therapy (HAART). Eur J Med Res. 2005 Sep 12;10(9):395-9.
PMID: 16183552
citation: Reinsch N, Kahlert P, Esser S, Sundermeyer A, Neuhaus K, Brockmeyer N, Potthoff A, Erbel R, Buck T, Neumann T. Echocardiographic findings and abnormalities in HIV-infected patients: results from a large, prospective, multicenter HIV-heart study. Am J Cardiovasc Dis. 2011;1(2):176-84. Epub 2011 Jul 30.
PMID: 22254197
citation: Lind A, Reinsch N, Neuhaus K, Esser S, Brockmeyer NH, Potthoff A, Pankuweit S, Erbel R, Maisch B, Neumann T. Pericardial effusion of HIV-infected patients ? Results of a prospective multicenter cohort study in the era of antiretroviral therapy. Eur J Med Res. 2011 Nov 10;16(11):480-3. doi: 10.1186/2047-783x-16-11-480.
PMID: 22027640
citation: Gelbrich B, Neumann T, Esser S, Potthoff A, Reinsch N, Hower M, Dannhauer KH, Loeffler M, Brockmeyer NH, Erbel R, Gelbrich G; HIV-HEART Study Investigative Group, Competence Networks Heart Failure and HIV/AIDS. Oral health and the heart - does HIV infection open a pathophysiological gateway? Int J Cardiol. 2011 Sep 1;151(2):254-7. doi: 10.1016/j.ijcard.2011.06.081. Epub 2011 Jul 18. No abstract available.
PMID: 21764468
citation: Reinsch N, Neuhaus K, Esser S, Potthoff A, Hower M, Mostardt S, Neumann A, Brockmeyer NH, Gelbrich G, Erbel R, Neumann T; German Competence Network Heart Failure; German Competence Network for HIV/AIDS. Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study. Eur J Prev Cardiol. 2012 Apr;19(2):267-74. doi: 10.1177/1741826711398431. Epub 2011 Feb 28.
PMID: 21450595
citation: Reinsch N, Neuhaus K, Esser S, Potthoff A, Hower M, Brockmeyer NH, Erbel R, Neumann T; German Competence Network for Heart Failure; German Competence Network for HIV AIDS. Prevalence of cardiac diastolic dysfunction in HIV-infected patients: results of the HIV-HEART study. HIV Clin Trials. 2010 May-Jun;11(3):156-62. doi: 10.1310/hct1103-156.
PMID: 20739268
citation: Potthoff A, Brockmeyer NH, Gelbrich G, Neuhaus K, Esser S, Reinsch N, Hower M, Mostardt S, Neumann A, Neumann T; Competence Center Cardiac Insufficiency and the Competence Network HIV/AIDS. Lipodystrophy - a sign for metabolic syndrome in patients of the HIV-HEART study. J Dtsch Dermatol Ges. 2010 Feb;8(2):92-8. doi: 10.1111/j.1610-0387.2009.07330.x. Epub 2009 Dec 14. English, German.
PMID: 20002869
responsible party type: Principal Investigator
investigator affiliation: University Hospital, Essen
investigator full name: Stefan Esser M.D.
investigator title: Academic Director
mesh term: Heart Failure
mesh term: Heart Diseases
mesh term: Coronary Disease
mesh term: Coronary Artery Disease
mesh term: Myocardial Ischemia
mesh term: Metabolic Syndrome